Quick Takeaways
- INDP - Indaptus Therapeutics, Inc. has 24 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 24 Insiders of Indaptus Therapeutics, Inc.
- Symbol
- INDP on Nasdaq
- Location
- New York, NY
What Changed
- No meaningful buy/sell imbalance is currently visible in the one-year window.
- Activity will update as new Forms 3/4/5 are filed.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsInsider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 07 May 2025.
Buys
$0
Shares: 0
Insiders: 0
Sells
$0
Shares: 0
Insiders: 0
Net
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Indaptus Therapeutics, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Yun Yao | 10%+ Owner | $122,189,610 | Mixed | 23 Mar 2026 | ||
| SINO LION VENTURES Ltd | 10%+ Owner | $113,180,560 | Mixed | 23 Mar 2026 | ||
| Junyi Dai | Chief Executive Officer | $32,736,375 | Mixed | 23 Mar 2026 | ||
| Glen R. Anderson | 10%+ Owner | $2,785,536 | Filing P/S | 10 Aug 2023 | ||
| Hoonmo Lee | Director | $1,626,157 | Mixed | 04 Aug 2021 | ||
| Jeffrey A. Meckler | Co-Chief Executive Officer, Director | $605,305 | Mixed | 11 Feb 2026 | ||
| Michael James Newman | CSO and Director, Director | $205,180 | Mixed | 22 Dec 2025 | ||
| Walt Addison Linscott | Chief Operating Officer | $110,484 | Mixed | 22 Dec 2025 | ||
| Avraham Ben-Tzvi | Director | $68,272 | Mixed | 23 Dec 2025 | ||
| Matthew Charles McMurdo | Director | $54,750 | Mixed | 26 Feb 2026 | ||
| Nir Sassi | Chief Financial Officer | $54,318 | Mixed | 22 Dec 2025 | ||
| Roger J. Waltzman | Chief Medical Officer | $5,325 | Mixed | 09 Oct 2024 | ||
| Boyan Vesselinov Litchev | Chief Medical Officer | $2,691 | Mixed | 01 Feb 2022 | ||
| Brian O'Callaghan | Director | $976 | Mixed | 30 Sep 2022 | ||
| Mark J. Gilbert | Director | $888 | Mixed | 10 Jun 2025 | ||
| Robert Martell | Director | $888 | Mixed | 10 Jun 2025 | ||
| David E. Lazar | Director | $0 | Mixed | 23 Mar 2026 | ||
| Hila Karah | Director | $0 | Mixed | 10 Jun 2025 | ||
| Anthony J. Maddaluna | Director | $0 | Mixed | 10 Jun 2025 | ||
| Roger Pomerantz | Director | $0 | Mixed | 10 Jun 2025 | ||
| William B. Hayes | Director | $0 | Mixed | 10 Jun 2025 | ||
| David Natan | Director | Mixed | 08 Jan 2026 | |||
| Qinglai Lu | Director | Mixed | 08 Apr 2026 | |||
| Jerome D. Jabbour | Director | Mixed | 26 Feb 2026 |
Top shareholders of Indaptus Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Yun Yao |
3/4/5
13D/G
|
10%+ Owner · Yao Yun |
37%
from 13D/G
|
41,991,000
|
$122,189,610 | — | 23 Mar 2026 | |
| SINO LION VENTURES Ltd |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
38,895,000
|
$113,180,560 | — | 23 Mar 2026 | |
| Junyi Dai |
3/4/5
|
Chief Executive Officer |
—
class O/S missing
|
11,250,000
|
$32,736,375 | — | 23 Mar 2026 | |
| Glen R. Anderson |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,190,400
|
$2,785,536 | — | 10 Aug 2023 | |
| Hoonmo Lee |
3/4/5
|
Director |
—
mixed-class rows
|
708,272
mixed-class rows
|
$1,626,157 | — | 04 Aug 2021 | |
| David E. Lazar |
13D/G
3/4/5
|
Lazar David E. · Director |
48%
|
2,064,000
|
$949,440 | -$50,110,560 | 23 Mar 2026 | |
| Jeffrey A. Meckler |
3/4/5
13D/G
|
Co-Chief Executive Officer, Director · Jeffery A. Meckler |
13%
from 13D/G
|
258,753
mixed-class rows
|
$605,305 | — | 11 Feb 2026 | |
| Michael James Newman |
3/4/5
13D/G
|
CSO and Director, Director · Newman Michael James |
5.4%
from 13D/G
|
101,074
|
$205,180 | — | 22 Dec 2025 | |
| Walt Addison Linscott |
3/4/5
|
Chief Operating Officer |
—
class O/S missing
|
54,426
|
$110,484 | — | 22 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
—
class O/S missing
|
29,002
|
$84,396 | — | 31 Dec 2025 | |
| Avraham Ben-Tzvi |
3/4/5
|
Director |
—
mixed-class rows
|
50,100
mixed-class rows
|
$68,272 | — | 23 Dec 2025 | |
| Matthew Charles McMurdo |
3/4/5
|
Director |
—
class O/S missing
|
25,000
|
$54,750 | — | 26 Feb 2026 | |
| Nir Sassi |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
26,758
|
$54,318 | — | 22 Dec 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
—
class O/S missing
|
3,151
|
$9,169 | — | 31 Dec 2025 | |
| Roger J. Waltzman |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
75,000
|
$5,325 | — | 09 Oct 2024 | |
| Boyan Vesselinov Litchev |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
1,150
|
$2,691 | — | 01 Feb 2022 | |
| Brian O'Callaghan |
3/4/5
|
Director |
—
class O/S missing
|
13,750
|
$976 | — | 30 Sep 2022 | |
| Mark J. Gilbert |
3/4/5
|
Director |
—
class O/S missing
|
12,500
|
$888 | — | 10 Jun 2025 | |
| Robert Martell |
3/4/5
|
Director |
—
class O/S missing
|
12,500
|
$888 | — | 10 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
—
class O/S missing
|
25
|
$73 | — | 31 Dec 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
—
class O/S missing
|
17
|
$49 | — | 31 Dec 2025 | |
| Roger Pomerantz |
3/4/5
|
Director |
—
class O/S missing
|
30,000
|
— | — | 10 Jun 2025 | |
| David Natan |
3/4/5
|
Director |
—
class O/S missing
|
25,000
|
— | — | 08 Jan 2026 | |
| Jerome D. Jabbour |
3/4/5
|
Director |
—
class O/S missing
|
25,000
|
— | — | 26 Feb 2026 | |
| Anthony J. Maddaluna |
3/4/5
|
Director |
—
class O/S missing
|
12,500
|
— | — | 10 Jun 2025 | |
| Hila Karah |
3/4/5
|
Director |
—
class O/S missing
|
12,500
|
— | — | 10 Jun 2025 | |
| William B. Hayes |
3/4/5
|
Director |
—
class O/S missing
|
12,500
|
— | — | 10 Jun 2025 |
Recent Insider Transactions by Companies or Individuals for Indaptus Therapeutics, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| David E. Lazar | INDP | Series AAA Convertible Non-Redeemable Preferred Stock | Sale | -100% | -700,000 | 0 | 23 Mar 2026 | Direct | ||
| David E. Lazar | INDP | Series AA Convertible Non-Redeemable Preferred Stock | Sale | -65.6% | -196,800 | 103,200 | 23 Mar 2026 | Direct | ||
| Jerome D. Jabbour | INDP | Option to Buy Common Stock | Award | 25,000 | 25,000 | 26 Feb 2026 | Direct | |||
| Jeffrey A. Meckler | INDP | Warrants (right to buy) | Award | 16,688 | 12,136 | 11 Feb 2026 | Direct | |||
| Jeffrey A. Meckler | INDP | Warrants (right to buy) | Disposed to Issuer | -100% | -16,688 | 0 | 11 Feb 2026 | Direct | ||
| Avraham Ben-Tzvi | INDP | Common Stock | Award | 25000% | 25,000 | 25,100 | 20 Jan 2026 | Direct | ||
| David Natan | INDP | Option to Buy Common Stock | Award | 25,000 | 25,000 | 07 Jan 2026 | Direct | |||
| Avraham Ben-Tzvi | INDP | Option to Buy Common Stock | Award | 25,000 | 25,000 | 23 Dec 2025 | Direct | |||
| Nir Sassi | INDP | Common Stock | Award | 26,758 | 26,758 | 22 Dec 2025 | Direct | |||
| Jeffrey A. Meckler | INDP | Common Stock | Award | 1627.2% | 216,617 | 229,929 | 22 Dec 2025 | Direct | ||
| Michael James Newman | INDP | Common Stock | Award | 106.8% | 52,204 | 101,074 | 22 Dec 2025 | Direct | ||
| Walt Addison Linscott | INDP | Common Stock | Award | 1088420% | 54,421 | 54,426 | 22 Dec 2025 | Direct | ||
| Jeffrey A. Meckler | INDP | Common Stock | Award | 83.8% | 6,068 | 13,312 | 27 Jul 2025 | Direct | ||
| Jeffrey A. Meckler | INDP | Common Stock Warrants | Award | 266.6% | 12,136 | 16,688 | 27 Jul 2025 | Direct | ||
| Hila Karah | INDP | Stock Option (right to buy) | Award | 12,500 | 12,500 | 10 Jun 2025 | Direct | |||
| Robert Martell | INDP | Stock Option (right to buy) | Award | 12,500 | 12,500 | 10 Jun 2025 | Direct | |||
| William B. Hayes | INDP | Stock Option (right to buy) | Award | 12,500 | 12,500 | 10 Jun 2025 | Direct | |||
| Anthony J. Maddaluna | INDP | Stock Option (right to buy) | Award | 12,500 | 12,500 | 10 Jun 2025 | Direct | |||
| Roger Pomerantz | INDP | Stock Option (right to buy) | Award | 30,000 | 30,000 | 10 Jun 2025 | Direct | |||
| Mark J. Gilbert | INDP | Stock Option (right to buy) | Award | 12,500 | 12,500 | 10 Jun 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.